Ligand preclinical data

LGND reported that Targretin may have efficacy in breast cancer and diabetes, as indicated by preclinical testing. Presenting at the Bear, Stearns conference in New York, the company said the data show the drug's ability to decrease blood glucose, triglycerides, and insulin levels in mouse models of diabetes. A rat model of breast cancer showed that Targretin reduced incidence of tumor at least as effectively as did tamoxifen, without the reduction in body weight produced by tamoxifen. Both new indications for the drug will be pursued.

To test the possible anti-diabetic action of the retinoid, groups of 15 mice with either the db/db or ob/ob mutation were treated with Targretin or an investigational anti-diabetic drug (a thiazolidinedione), or placebo. After 14 days of treatment with three doses daily, the retinoid decreased blood glucose by 40 percent, triglycerides by 30 percent, and insulin by 20 percent. This anti-diabetic action was maintained during the course of the study, and was as effective as that produced by the investigational drug. Targretin also demonstrated additive activity with the second drug. ...